ATOSSA THERAPEUTICS, INC.

(ATOS)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
1.170 USD   +4.46%
06/06Atossa Files IND to FDA for Oral (Z)-Endoxifen Capsules for Patients With ER+/HER2- Breast Cancer
MT
06/06ATOSSA THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
06/02Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Earnings Flash (ATOS) ATOSSA THERAPEUTICS Reports Q1 Loss $-0.04

05/09/2022 | 04:32pm EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
ATOS SE 2.39% 13.72 Real-time Quote.-63.31%
ATOSSA THERAPEUTICS, INC. 4.46% 1.17 Delayed Quote.-26.88%
All news about ATOSSA THERAPEUTICS, INC.
06/06Atossa Files IND to FDA for Oral (Z)-Endoxifen Capsules for Patients With ER+/HER2- Bre..
MT
06/06ATOSSA THERAPEUTICS, INC. : Regulation FD Disclosure (form 8-K)
AQ
06/02Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as ..
AQ
05/18Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conferen..
AQ
05/16ATOSSA THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/09Earnings Flash (ATOS) ATOSSA THERAPEUTICS Reports Q1 Loss $-0.04
MT
05/09ATOSSA THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ..
AQ
05/09Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corpora..
AQ
05/09Atossa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
04/28Atossa Therapeutics to Present at the Q2 Investor Summit Conference
AQ
More news
Analyst Recommendations on ATOSSA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -25,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -5,85x
Yield 2022 -
Capitalization 148 M 148 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 7
Free-Float 100,0%
Chart ATOSSA THERAPEUTICS, INC.
Duration : Period :
Atossa Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ATOSSA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 1,17 $
Average target price 5,75 $
Spread / Average Target 391%
EPS Revisions
Managers and Directors
Steven C. Quay Chairman, President & Chief Executive Officer
Kyle Guse CFO, Secretary & Chief Accounting Officer
Devon Payne Director-Clinical Operations
Bernadine Heather Fraser VP-Clinical, Regulatory & CMC Division
Delly Behen Vice President-Administration & Human Resource
Sector and Competitors
1st jan.Capi. (M$)
ATOSSA THERAPEUTICS, INC.-26.88%148
MODERNA, INC.-43.20%57 385
IQVIA HOLDINGS INC.-24.22%40 468
LONZA GROUP AG-32.67%39 851
SEAGEN INC.16.00%33 010
CELLTRION, INC.-13.38%18 371